Refine by
Heart Failure Articles & Analysis
271 news found
The appointments enable Hemostemix to sell VesCell™ in Florida to podiatrist and vascular surgeons, to treat PAD & CLTI; and to cardiologist to treat Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and Congestive Heart Failure. The additions to the leadership team are top-tier talent with a proven track record of success in the ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Cardiovascular disease models are essential tools used in the research of heart-related conditions. These models can be biochemical, physiological, computational, or clinical, and they aim to simulate various aspects of cardiovascular health, disease progression, and responses to interventions. ...
Digoxin is used primarily to improve the heart’s ability to pump blood in patients with congestive heart failure (CHF) and to treat problems such as high blood pressure. It is also used to help normalize certain heart arrhythmias (abnormal types of heartbeats). Another is the Anti-Fluorescien monoclonal antibody (Catalog # ...
A third site is an academic medical center and is recognized as one of the top heart failure centers in the U.S. with more than 800 physicians in 200 specialties serving patients in Virginia. ...
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure ...
Tune into this episode of HF Beat to hear our co-hosts interview Paul Heidenreich, MD, FHFSA, a co-author of the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure about economic considerations in the management of HF. On "From Failure to Function", Priya dives into the late breaking trials from ACC.23 and Michael reviews three ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which ...
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart ...
Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass. Blood volume analysis (BVA) was used in hospitalized heart failure ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. ...
CARLSBAD, Calif., March 7, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The application has been given ...
March 2023's Heart Failure Awareness 365 campaign is focusing on: Nutrition/Diet/Exercise. While these three things are important for any individual's everyday health, they can have an even bigger impact if you're living with heart failure. Not only can properly managing these parts of your health alleviate heart ...
We are proud to share that AstraZeneca has launched “That’s Understandable” – a podcast hosted by Brendan McEvoy, US Head of External Communications – who will be connecting with various experts to break down the multitude of factors affecting the healthcare industry. These conversations will touch on a variety of issues at the intersection of healthcare, business, ...
The Heart Failure Society of America is your association and we would love for you to get involved. Volunteering for committee and leadership positions at HFSA helps you develop professionally, facilitates networking with other heart failure leaders, and will positively impact the heart failure ...
https://www.termis.org/wc2018/ On September 7th, CSO speaks about monogenic disease modeling using NuHeart™ technology during TERM for heart, blood vessel & lung session. 99-O-5: Personalized micro-3D human heart tissues for orphan drug development Tetsuro Wakatsuki,Neil Daily,Pinar Kemanli, Michael Greenberg,Jennifer Strande InvivoSciences, Inc. Madison Wisconsin, USA, ...
Our lead product is 3D cardiac engineered heart tissues (EHTs) fabricated from human induced pluripotent stem cell (iPSC) derived cardiomyocytes. ...
Cardiovascular diseases (CVDs) are the number one cause of death globally. The high failure rate of cardiovascular clinical trials (e.g., 11% of Phase II failure between 2008-11) indicates that there is an unmet need for more focused approaches, including personalized drug discovery for specific patient groups or even for rare genetic diseases, i.e., orphan drug ...
Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and ...